News
Rofecoxib caused excess heart disease
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7485.212-a (Published 27 January 2005) Cite this as: BMJ 2005;330:212
- Susan Mayor
- London
The COX 2 (cyclo-oxygenase-2) inhibitor rofecoxib (Vioxx) could have caused an estimated 88 000-140 000 excess cases of serious coronary heart disease in the United States since its launch in 1999, says a study published this week. The drug was withdrawn in September last year after being linked to increased cardiac deaths (BMJ 2004;329: 816).
The study analysed a cohort of all patients age 18-84 years receiving health care from a managed care organisation, Kaiser Permanente, in California, who were treated with …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £157 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.